<DOC>
	<DOCNO>NCT00003613</DOCNO>
	<brief_summary>This phase I trial study side effect best dose carmustine give together O ( 6 ) -benzylguanine treat patient stage I stage II cutaneous T-cell lymphoma respond previous treatment . Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining one drug may kill cancer cell</brief_summary>
	<brief_title>O6-benzylguanine Carmustine Treating Patients With Stage IA-IIA Cutaneous T-cell Lymphoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine kinetics AGT depletion CTCL skin lesion . II . To determine toxicity low dose BCNU plus O6BG . OUTLINE : This dose-escalation study carmustine . Patients receive O6-benzylguanine IV 1 hour follow topical carmustine every 2 week . Treatment continue absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos carmustine maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . Patients follow 6 week .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<mesh_term>O ( 6 ) -benzylguanine</mesh_term>
	<criteria>Histologically confirm CTCL , stag IAIIA Performance status ECOG grade 0 , 1 , 2 Patients must recover toxicity prior treatment receive CTCL therapy emoliation least 4 week Patients must sign consent form indicate investigational nature treatment potential side effect WBC &gt; 4,000/ul ANC &gt; 2,000/ul Platelets &gt; 100,000/ul Bilirubin &lt; 1.5 mg/dL SGOT within normal range Prothrombin time within normal range Creatinine = &lt; 1.5 mg/dL creatinine clearance &gt; = 70 ml/min Calcium electrolytes normal Glucosecontrolled ( diet insulin ) diabetes permitted DLCO &gt; 80 % normal exception patient demonstrate clinically normal lung function base history , physical examination , chest xray interpret principal investigator Only patient biopsiable tumor willing undergo several biopsy eligible Must fail 1 conventional treatment topical corticosteroid ; include UVB , PUVA , topical mechlorethamine , electron beam , photopheresis , chemotherapy immunomodulatory agent cytokines Patients prior treatment nitrosourea Patients know central nervous system involvement primary CNS malignancy ineligible Patients performance status ECOG grade 3 4 Pregnant woman , woman breast feeding infant , woman reproductive potential practicing adequate contraception , potential toxicity fetus infant Patients active infection Patients pulmonary disease determine history , physical examination , chest Xray pulse oximetry CTCL patient stage IIBIVB disease</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>